CC
EBS icon

Centiva Capital’s Emergent Biosolutions EBS Stock Holding History

Centiva Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,544
Closed -$263K – 1865
2024
Q3 		$263K Sell
31,544
-52,530
-62% -$478K 0.01% 1657
2024
Q2 		$573K Buy
+84,074
New +$362K 0.01% 1069
2019
Q4 		– Sell
-7,406
Closed -$387K – 833
2019
Q3 		$387K Buy
+7,406
New +$345K 0.02% 383

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Centiva Capital's EBS Position: Q4 2024 in Review

Centiva Capital sold out of Emergent Biosolutions (EBS) in Q4 2024, closing a stake of 31,544 shares — an estimated $263K sold.

Centiva Capital first reported a position in EBS in Q3 2019 and held it in 3 quarters. The position peaked at $573K in Q2 2024. 156 funds tracked by Wall St. Rank hold EBS as of Q4 2024.

  • Centiva Capital reported no remaining Emergent Biosolutions position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 31,544 Emergent Biosolutions shares in Q4 2024, an estimated $263K.
  • Centiva Capital first reported a position in Emergent Biosolutions in Q3 2019 and held it in 3 quarters.
  • Centiva Capital's Emergent Biosolutions position peaked at $573K in Q2 2024.
  • 156 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.